Abstract:The NLRP3 inflammasome is a critical component of innate immunity, which defends internal and external threats. However, inappropriate activation of the NLRP3 inflammasome induces various human diseases. In this study, we discovered and synthesized a series of tetrahydroquinoline inhibitors of NLRP3 inflammasome. Among these analogues, compound 6 exhibited optimal NLRP3 inhibitory activity. In vitro studies indicated that compound 6 directly bound to the NACHT domain of NLRP3 but not to protein pyrin domain (PYD) or LRR domain, inhibited NLRP3 ATPase activity, and blocked ASC oligomerization, thereby inhibiting NLRP3 inflammasome assembly and activation. Compound 6 specifically inhibited the NLRP3 inflammasome activation, but had no effect on the activation of NLRC4 or AIM2 inflammasomes. Furthermore, in the dextran sulfate sodium (DSS)-induced colitis mouse model, compound 6 exhibited significant anti-inflammatory activity through inhibiting NLRP3 inflammasome in vivo. Therefore, our study provides a potent NLRP3 inflammasome inhibitor, which deserves further structural optimization as a novel therapeutic candidate for NLRP3-driven diseases.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01924?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01924</a>.1H NMR, 13C NMR, and HPLC spectra analysis of all synthetic compounds; amino acid sequences of NLRP3 PYD domain, NACHT domain, and LRR domain; pharmacophore generation; pharmacophore and docking screening; small molecules in training set and testing set; and the activity tests of selected ligands (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_002.csv">CSV</a>)Recommended compound characterization checklist (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_003.pdf">PDF</a>)Recommended compound characterization checklist (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_004.xls">XLS</a>)This article has not yet been cited by other publications.

Spirodalesol, an NLRP3 Inflammasome Activation Inhibitor.

Spirodalesol Analog 8A Inhibits NLRP3 Inflammasome Activation and Attenuates Inflammatory Disease by Directly Targeting Adaptor Protein ASC.

Novel Isoalantolactone-Based Derivatives as Potent NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization

Discovery of Novel Pterostilbene-Based Derivatives as Potent and Orally Active NLRP3 Inflammasome Inhibitors with Inflammatory Activity for Colitis

Discovery, Total Synthesis, and Anti‐inflammatory Evaluation of Naturally Occurring Naphthopyrone‐Macrolide Hybrids as Potent NLRP3 Inflammasome Inhibitors

Discovery of Triazinone Derivatives as Novel, Specific, and Direct NLRP3 Inflammasome Inhibitors for the Treatment of DSS-Induced Ulcerative Colitis

Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis

Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors

A novel sorbicillinoid compound as a potent anti-inflammation agent through inducing NLRP3 protein degradation

Diterpenoids with novel 6/5-5 spiro tricyclic skeleton from Orthosiphon wulfenioides and their NLRP3 inflammasome inhibitory activity

Synthesis and Anti-Inflammatory Bowel Disease Activity of Pterostilbene Derivatives

Functional Characterization of an Arylsulfonamide-Based Small-Molecule Inhibitor of the NLRP3 Inflammasome

Saponins as potential novel NLRP3 inflammasome inhibitors for inflammatory disorders

Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases

Design, synthesis and biological evaluation of tanshinone IIA derivatives as NLRP3 inflammasome inhibitors

Development of Novel Tetrahydroquinoline Inhibitors of NLRP3 Inflammasome for Potential Treatment of DSS-Induced Mouse Colitis

NLRP3 Inflammasome Inhibitor INF39 Attenuated NLRP3 Assembly in Macrophages.

Deep-Learning-Driven Discovery of SN3-1, a Potent NLRP3 Inhibitor with Therapeutic Potential for Inflammatory Diseases

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

Erianin: A Direct NLRP3 Inhibitor With Remarkable Anti-Inflammatory Activity

Design, synthesis, and biological evaluation of oridonin derivatives as novel NLRP3 inflammasome inhibitors for the treatment of acute lung injury